Jonathan M. Adams M.B.A., MBA is the Exec. VP of Liver Disease Program at BioVie.
As the Exec. VP of Liver Disease Program of BioVie, the total compensation of Mr MBA at BioVie is 267,199$. There are no executives at BioVie getting paid more.
Mr MBA is 58, he's been the Exec. VP of Liver Disease Program of BioVie since . There are 7 older and 3 younger executives at BioVie. The oldest executive at BioVie Inc. is Steven Gorlin, 82, who is the Director.
Jonathan's mailing address filed with the SEC is C/O BIOVIE, 9120 DOUBLE DIAMOND PARKWAY, SUITE 1400, RENO, NV, 89521.
Over the last 9 years, insiders at BioVie have traded over 352,740$ worth of BioVie stock and bought 67,100 units worth 464,015$ . The most active insiders traders include Terren S Peizer、Steve Gorlin、Richard J Berman. On average, BioVie executives and independent directors trade stock every 122 days with the average trade being worth of 301,811$. The most recent stock trade was executed by Cuong V Do on 4 March 2024, trading 10,000 units of BIVI stock currently worth 28,900$.
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California.
BioVie executives and other stock owners filed with the SEC include: